Education
About Us
Working with TipRanks
Follow Us
Alphatec Holdings (DE:L1Z1)
FRANKFURT:L1Z1
L1Z1 Stock Chart & Stats
€10.56
€0.30(3.41%)
At close: 4:00 PM EST
€10.56
€0.30(3.41%)
Day’s Range― - ―
52-Week Range€8.15 - €19.28
Previous CloseN/A
Volume150.00
Average Volume (3M)42.00
Market Cap
€1.66B
Enterprise Value€2.37B
Total Cash (Recent Filing)€160.81M
Total Debt (Recent Filing)€619.95M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Apr 30, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding151,356,610
10 Day Avg. Volume0
30 Day Avg. Volume42
Financial Highlights & Ratios
PEG Ratio1.46
Price to Book (P/B)87.63
Price to Sales (P/S)4.13
P/FCF Ratio1.14K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.14Price Target Upside100.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.23
Revenue Forecast (FY)€777.37M
Bulls Say, Bears Say
Bulls Say
Enabling Technologies And RoboticsCommercial approval and rollout of the compact Valence robotic navigation system alongside technologies such as EOS Insight and SafeOp neuromonitoring are expanding procedural capabilities and encouraging adoption for more complex spine surgeries.
Profitability And Financial StabilityManagement's raised profitability and adjusted EBITDA guidance, paired with revenue modestly above expectations and an increased cash balance, signals improving margins and stronger earnings power.
Surgeon Adoption And UtilizationRecord levels of new surgeon adoption and rising utilization among existing surgeons support expectations for higher procedure volumes without a proportional increase in the active user base.
Bears Say
Execution And Regulatory RiskExposure to commercial execution challenges, potential partnership setbacks, regulatory hurdles, financial constraints, and intellectual property disputes creates material risks that could impede expansion plans.
Market Sentiment And Stock VolatilityA sharp share sell-off that appeared disconnected from guidance and a raised profitability outlook has created investor confusion and added downward pressure on the stock.
Surgical Growth And Procedure MixSlowed surgical revenue growth and a shift toward simpler procedures have reduced revenue per surgery and are weighing on overall growth expectations.
Alphatec Holdings News
L1Z1 FAQ
What was Alphatec Holdings’s price range in the past 12 months?
Alphatec Holdings lowest stock price was €8.15 and its highest was €19.28 in the past 12 months.
What is Alphatec Holdings’s market cap?
Alphatec Holdings’s market cap is €1.66B.
When is Alphatec Holdings’s upcoming earnings report date?
Alphatec Holdings’s upcoming earnings report date is Apr 30, 2026 which is in 43 days.
How were Alphatec Holdings’s earnings last quarter?
Alphatec Holdings released its earnings results on Feb 24, 2026. The company reported €0.052 earnings per share for the quarter, beating the consensus estimate of €0.033 by €0.019.
Is Alphatec Holdings overvalued?
According to Wall Street analysts Alphatec Holdings’s price is currently Undervalued.
Does Alphatec Holdings pay dividends?
Alphatec Holdings does not currently pay dividends.
What is Alphatec Holdings’s EPS estimate?
Alphatec Holdings’s EPS estimate is -0.02.
How many shares outstanding does Alphatec Holdings have?
Alphatec Holdings has 151,356,610 shares outstanding.
What happened to Alphatec Holdings’s price movement after its last earnings report?
Alphatec Holdings reported an EPS of €0.052 in its last earnings report, beating expectations of €0.033. Following the earnings report the stock price went down -2.204%.
Which hedge fund is a major shareholder of Alphatec Holdings?
Currently, no hedge funds are holding shares in DE:L1Z1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alphatec Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.14 (100.17% Upside)
€21.14 (100.17% Upside)
Blogger Sentiment
Bullish
DE:L1Z1 Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $5.9M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
32.47%
12-Months-Change
Fundamentals
Return on Equity
-1760.45%
Trailing 12-Months
Asset Growth
2.00%
Trailing 12-Months
Company Description
Alphatec Holdings
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California.
L1Z1 Company Deck
L1Z1 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed a company with strong top‑line momentum, expanding profitability, improving gross margins, meaningful surgeon adoption, and a rich product and pipeline roadmap. Key positives include double‑digit revenue growth (20% Q4, 25% FY), substantial adjusted EBITDA expansion (61% Q4, +$63M FY), a solid cash position, and upgraded 2026 EBITDA guidance. Near‑term headwinds are limited and mostly operational or structural: modest full‑year free cash flow in 2025, international mix lowering per‑case revenue, a shift in seasonality that may complicate quarter‑to‑quarter cadence, and some investor pushback reflected in after‑hours trading. Overall, the highlights materially outweigh the lowlights.View all DE:L1Z1 earnings summariesL1Z1 Stock 12 Month Forecast
Average Price Target
€21.14
▲(100.17% Upside)
Technical Analysis
Options Prices
Currently, No data available
---